DOCSLIB.ORG

Radiant Pharmaceuticals Limited

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Pharma Profile Department of Pharmacy, Varendra University Preface This is a small initiative to summarize the short profile of the top tire pharmaceutical companies of Bangladesh. Information is collected from websites of different companies and some internet based blogs. So there may have some inconvenient errors. Any correction, suggestion or advice will be highly appreciated. Students of 3rd batch, Department of Pharmacy, Varendra University spend their effort for this initiative as a part of learning. Thanks to them for their effort and interest. If this initiative become helpful to the Pharmacy students that will be my pleasure and inspiration. ………………………………………………………. Md. Sanowar Hossain M. Pharm. (Rajshahi University) Lecturer, Department of Pharmacy Varendra University Email: [email protected] Thanks to 3rd Batch, Department of Pharmacy, VU Radwanul Akbar Mehedi Hasan Nishat Fariha Sandhi Tamima Afrose S. M. Abdul Barik Md. Mosharrof Hasan Md. Rafiul Islam Nuzhat Tasnim Amin Fatema Tuz Zohora Khadiza Sultana Al Romon For Samaun Rashid Emraul Kayesh Nazmul Islam Bokhtear Sarkar your Rashidul Islam Amatur Rakiba Munmun Tania Afrin Rabaka Sultana contribution Jannatul Farhana Mohd. Mosiur Rahman Boby Khatun Farjana Yeasmin Nusrat Jahan Samia Tasnim Saurov Chakroborty Ariful Islam Anjira Ohomina Saida Aktar Pinky Nishat Tasnim Akhter Zaki Numeri Umme Farzana Zahan Abdul Mannan Index Topic Page Square Pharmaceuticals 1-2 Incepta Pharmaceuticals 3-4 Beximco Pharmaceuticals 5-6 Opsonin Pharmaceuticals 7-8 Renata Pharmaceuticals 9-10 Aristo Pharma 11-12 SK+F Pharmaceuticals 13-14 ACI Limited 15-16 ACME Laboratories 17-18 Healthcare Pharmaceuticals 19-20 Drug International Limited 21-22 General Pharmaceuticals 23-24 Radiant Pharmaceuticals 25-26 Novo Nordisk Limited 27-28 Popular Pharmaceuticals 29-30 Unimed Unihealth 31-32 Novarties Limited 33-34 GSK Limited 35-36 Orion Pharma 37-38 Ibn Sina Pharmaceuticals 39-40 Beacon Pharmaceuticals 41-42 Ziska Pharmaceuticals 43-44 Globe Pharmaceuticals 45-46 Bio Pharma 47-48 Navana Pharmaceuticals 49-50 Pacific Pharmaceuticals 51-52 Delta Pharmaceuticals 53-54 SMC 55-56 Jayson Pharmaceuticals 57-58 Alco Pharmaceuticals 59-60 Kemico Pharmaceuticals 61-62 White Horse Pharmaceuticals 63-64 RAK Pharmaceuticals 65-66 Sharif Pharmaceuticals 67-68 Apex Pharma 69-70 Somatec Pharmaceuticals 71-72 Rangs Pharmaceuticals 73-74 Asiatic Laboratories 75-76 Ambee Pharmaceuticals 77-78 Edruc Limited 79-80 Silva Pharmaceuticals 81-82 Concord Pharmaceuticals 83-84 EDCL 85-86 Square Pharmaceuticals Limited Address Head Office Factory SQUARE Centre Square Pharmaceuticals Ltd. 48, Mohakhali C/A Dhaka 1212, Kaliakoir, Gazipur (Dhaka Unit) Bangladesh. Phone: +88-02-9859007, Square Pharmaceuticals Ltd. +88-02-8833047-56 Meril Road, Salgaria, Pabna. www.squarepharma.com.bd Establishment SQUARE today symbolizes a name – a state of mind. But its journey to the growth and prosperity has been no bed of roses. From the inception in 1958, it has today burgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player. Product Range SQUARE formulates and markets a comprehensive range of more than 400 products covering all major therapeutic areas, which come in vaccines, oral healthcare products, tablets, capsules, syrup, suspension, sterile eye drops, Page | 1 injectables, nasal sprays, creams, ointments, IV fluids, metered dose inhalers, dry powder inhalers, suppositories, lyophilized injectables, prefilled syringes etc., argrovet & pesticide products, herbal & neutraceuticals products, over-the-counter medicines. Market Position Square Pharmaceuticals Limited is the 1st company based on national sales (IMS- 4Q MAT 2015). Certificate: Square Pharmaceuticals Limited is approved by US FDA, ISO 9001: 1998, UKMHRA and TGA. Export The quality of SQUARE products, strengthened by its US-FDA & ISO 1998 certification, has bought success in Europe: UK, Denmark and Netherlands. Asia: Afghanistan, Bhutan, Cambodia, Fiji, Hong Kong, Iraq, Korea, Macau, Malaysia, Maldives, Myanmar, Nepal, Papua New Guinea, Palau, Sri Lanka, Tajikistan, The Philippines, Uzbekistan, Vietnam. Africa: Eritrea, Ivory Coast, Kenya, Libya, Malawi, Mauritania, Mauritius, Mozambique, Nigeria, Somalia, Tanzania, Uganda. Central and South America: Belize, Costa Rica, and Suriname. Major Product Product Name Generic Name Ace Paracetamol Seclo Omeprazol Flexi Aceclofenac Cotrim Cotrimoxazol Entacyd Aluminium hydroxide & Magnesium hydroxide Almex Albendazol Page | 2 Incepta Pharmaceuticals Limited Address Head Office Factory Incepta Pharmaceutical Bangladesh 40 Shahid Tajuddin Ahmed Sarani Dewan Idris Road, Jirabo, Savar Tejgaon I/A, Dhaka-1208. Bangladesh Dhaka. Bangladesh Phone: (+88 02) 8891688 - 703 Phone: (+88 02) 7792502-6 Fax: (+88 02) 8891190 Fax: (+88 02) 7792507 www.inceptapharma.com Establishment Incepta Pharmaceuticals Ltd. was established in Dhaka, Bangladesh in 1999. The company has a manufacturing facility located at Zirabo, Savar. A second larger manufacturing facility has been built in Dhamrai. Product Range Since its inception, Incepta Pharmaceuticals has been launching 742 products in the Bangladesh market. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid filled hard gelatin capsules, lyophilized injections, and human vaccines. Page | 3 Market Position Incepta Pharmaceuticals Limited is the 2nd company based on national sales (IMS- 4Q MAT 2015). Certificate Incepta Pharmaceuticals Ltd. received ISO 9001:2000 certification on 20 July 2011. Incepta also receives UK MHRA certificate on 19 March 2008. Export Incepta currently sells its product in many countries of Asia, Africa, Central America and has started to sell in Latin America and Europe. Incepta is taking special efforts to ensure presence in the rest of the globe. Currently the company is exploring distributorship, contract manufacturing, in licensing, technology partnership and many other forms of cooperation. Some Major Product Product Name Generic Name Reservix Aceclofenac Fixocard Amlodipine & Atenolol Tridosil Azithromycin Bisopro Bisoprolol Emixef Cefixime Beuflox Ciprofloxacin Disopan Clonazepam Klarix Clarithromycin Omenix Omeprazole Cavic C Vitamin C & Calcium Page | 4 Beximco Pharmaceuticals Limited Address Head Office Factory 19, Dhanmondi R/A, Road No. 7 Dhaka-1205, Bangladesh. Beximco Pharmaceuticals Limited Phone: +880-2-58611001-7 Squib road, Cheragali, Tongi, E-mail: [email protected] Gazipur, Bangladesh. Website: beximco-pharma.com Establishment Beximco Pharmaceuticals Limited Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs. Product Range Beximco Pharma produces 500+ products in different dosage forms covering broad therapeutic categories. These include antibiotics, gastro-intestinals, Page | 5 allergic disorders, anti-infectives, central nervous system, cough & cold, eye care, endocrine & diadetes, gastrointestinal, intravenous fluids, musculoskeletal, oncology, skin care, vitamins &minerals supplement, respiratory, analgesics, cardiovascular, antidiabetics and many others. Market Position Beximco Pharmaceuticals Limited is the 3rd company based on national sales (IMS- 4Q MAT 2015). Certificate Beximco Pharma is approved by US-FDA, UK MHRA and ISO-9001. Export Beximco Pharma has so far exported medicines to more than 40 countries around the world including USA, Singapore, MEDS and Kenyatta National Hospital, Kenya, CENABLAST in Chile, and Asthma Drug Facility (ADF) of France. Some Major Product Product Name Generic Name Acifix Rabeprazole Napa Paracetamol Neoceptin-R Ranitidine Azithrocin Azithromycin Aluminium hydroxide+Magnesium Lactamil hydroxide Calorate Calcium Orotate tablet Ultrafen Diclofenac Sodium Page | 6 Opsonin Pharma Limited Address Head Office Factory Opsonin Pharmaceutical Limited Opsonin Pharma Limited 30 New Eskaton Road Bagura Road, Barisal, Dhaka 1000 , Bangladesh Bangladesh Phone:+880 2-9332262 Establishment Opsonin Pharma Ltd. is a leading drug manufacturing company in Bangladesh. It was established in 1956 by honorable Late Abdul Khaleque Khan. Integrating the visionary imagination for basic industrial development in this country by Founder Chairman Late Abdul Khaleque Khan, Opsonin have already established a number of innovative & import substitute industrial units mainly in the pharmaceuticals and related sectors. The seed that was planted in the year 1956 now has become a tree. The way Opsonin walked though was not a smooth and plain one. After a thousand miles walk the plant of distilled water has now opened a new horizon in Bangladesh Pharma industry. From the inception Opsonin always believed in nation building activities. Opsonin’s cherished dream is to serve Page | 7 the mankind and the man behind the mankind. This dream has come into reality as a result of thousand miles throbbing walk of thousand people. Product Range The company is now manufacturing 276 brands with 661 SKUs as Pharmaceutical finished products.
Recommended publications
  • Pharmaceuticals in Bangladesh

    Pharmaceuticals in Bangladesh

    Public Disclosure Authorized DISCUSSION PAPER PUBLIC AND PRIVATE SECTOR APPROACHES TO IMPROVING PHARMACEUTICAL QUALITY Public Disclosure Authorized IN BANGLADESH Janet Bumpas Kees Kostermans Dinesh Nair Public Disclosure Authorized South Asia, Human Development Department THE WORLD BANK August 2007 Public Disclosure Authorized World Bank Discussion Paper August 2007 Table of Contents Acknowledgements......................................................................................................... v Foreword........................................................................................................................ vi Summary....................................................................................................................... vii 1. Introduction ............................................................................................................ 1 1.1 Background ......................................................................................................... 1 1.2 Objective ............................................................................................................. 1 1.3 Methodology ....................................................................................................... 1 2. The Global Pharmaceutical Industry................................................................... 2 2.1 R&D Based Pharmaceutical Firms...................................................................... 2 2.2 Generic Pharmaceutical Firms ...........................................................................
  • SQUARE Pharma Annual Report 2018-2019

    SQUARE Pharma Annual Report 2018-2019

    Annual Report 2018-2019 INSIDE THIS REPORT Year ended 30 June 2019 Key Highlight 05: 53rd AGM No�ce 06: Ten Principles of Global Compact (UN) Pg 02 08: The Founder 09: Board of Directors 10: Value Added Statement 11: Message from the Chairman Membeembersrs Mee�ng 12: 5 years Opera�onal Result No�ce 13: Statement from the MD 14: Together we are Strong Pg 05 16: Milestone of Excellence 18: Corporate Governance 26: We Export to 28: Directors’ Report (English) We Export to 36: Management Discussion & Analysis 45: Status of CGC Compliance 51: Directors’ Report (Bangla) Pg 26 59: Financial Profile 60: Auditors’ Report Directoectorrs’ Report 64-83: Consolidated Financial Statement Statement of Financial Posi�on Statement of Profit or Loss and Pg 28 other Comprehensive Income Statement of Changes in Equity Statement of Cash Flows Managementt’s 84-114: Standalone Financial Statement Statement of Fininanancicialal Posi�on Discussion & Analysis Statement of Profit or LoLoss andand other Compreprehensensivive InIncocome Pg Statement of ChanChanges in EqEquity 36 Statement of CasCash Flolows 115: Subsidiary Profile 128: Glimpse of 52nd AGAGM FiFinanancial 129: Proxy Form Profile 131: Corporate Innfo. & CoCommpplliiaanncce Pg 59 Square Pharmaceu�cals Ltd. Square Centre 48 Mohakhali Commercial Area Dhaka, Bangladesh Square Pharmaceuticals Ltd. ABOUT US SQUARE Pharma, the largest pharmaceuticals company in the Country, is a trusted name in the pharmaceuticals sector of Bangladesh. Like most indigenous concern it made its debut in a humble way in 1958 as a Partnership Firm under the leadership of Late Samson H Chowdhury. The following year, 12 working people, occupied floor space of 3,000 sq.
  • Problems of Export of Pharmaceutical Products from Bangladesh : an Analysis

    Problems of Export of Pharmaceutical Products from Bangladesh : an Analysis

    Journal of Business Studies, Vol. XXXVI, No. 3, December 2015 Problems of Export of Pharmaceutical Products from Bangladesh : An Analysis Dr. Samir Kumar Sheel* Abstract: The pharmaceutical industry is one of the most technologically advanced sectors in current Bangladesh. It has grown in the last two decades at a rapid rate. Efficiency of the professionals and innovative ideas of the people involved in this industry are the key factors for these developments. The industry consists of about 275 pharmaceutical companies which are providing almost 97 percent of the local demand for drugs. Drastic developments in the pharmaceutical sector have enabled Bangladesh to export medicine to global markets. This sector has the opportunity to flourish as the second leading export sector of Bangladesh very soon if it keeps its momentum. But some obstacles are there to achieve that target. Therefore the present study is to find out the problems of export of pharmaceutical products from Bangladesh. The study reviles that the country has tremendous opportunities for pharma export, particularly for value added generics in the regulated markets. The pharmaceutical companies are successful in local market with huge import substitutions and now flourishing in the international market mostly due to the opportunity of patent exemption by the TRIPs till 2033. To boost up the export performance of this sector, some impediments have been indentified and also some recommendations have been made to the government and other concerning authorities for API Park, bioequivalence test laboratory, central drug testing laboratory, cash incentives, problems in remittance transfer and sample sending etc. Keywords : TRIPS, API, GMP, DTL, NCL, DMF, SEZ, NIPER.
  • Internship Report

    Internship Report

    Internship Report “Recruitment & Selection Process of Square Pharmaceuticals Ltd.” Supervised By Sohana Wadud Ahmad Lecturer BRAC Business School Course: BUS 400 (Internship) Semester: Spring 2015 Submitted By Parmina Moumita Mazumder ID: 11104106 BRAC Business School BRAC University INTERNSHIP REPORT ON “RECRUITMENT & SELECTION PROCESS OF SQUARE PHARMACEUTICALS LTD” Letter of Transmittal 30th April, 2015 Sohana Wadud Ahmad Lecturer BRAC Business School Brac University 66, Mohakhali C/A Dhaka 1212 Subject: Seeking permission to submit Internship report on “Recruitment & Selection Process of Square Pharmaceuticals Limited” Dear Madam, It is my privilege to let you know that as partial fulfillment of the requirements for the degree of Bachelor of Business Administration (BBA), I have completed my Internship program in Square Pharmaceuticals Limited, CHQ, Human Resource Department. This report is prepared based on my three months internship practical experience. The report focuses mainly on the overall Human Resource Management practices regarding recruitment & selection process in Square Pharmaceuticals Limited. The study has given me the opportunity to get a deeper insight and use my theoretical knowledge in practical world. It had also helped me to learn practically what I have studied in my BBA program. During my stay there, I had work in the Human Resource Department under the supervision of Senior Executive Mr. Tariqul Bari. It has been a great privilege to work in such a friendly environment and learn numerous practical and confidential things. Finally, thank you for your supportive thought, valuable suggestions, guidelines and kind consideration for formulating ideas and developing the structure of the paper. I would be my obligation to provide you with any required clarification regarding the project.
  • Report on the Recruitment and Selection Process Of

    Report on the Recruitment and Selection Process Of

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by BRAC University Institutional Repository REPORT ON THE RECRUITMENT AND SELECTION PROCESS OF SQUARE PHARMACEUTICAL LTD INTERNSHIP RESEARCH REPORT ON Recruitment and Selection Process of Square Pharmaceuticals Ltd Supervised By: Dr. Hafiz G.A. Siddiqi Professor Emeritus BRAC Business School Submitted By: Abida Ferdous ID- 10304070 BRAC Business School Date of Submission 25th June, 2014 LETTER OF TRANSMITTAL Dr. Hafiz G.A. Siddiqi Professor Emeritus BRAC Business School BRAC University Subject: Submission of Internship Report. Dear Sir I have the honor to state that, I have prepared this report on Human Resource Policies & Practices of Square Pharmaceuticals Ltd., with special emphasis on Recruitment and Selection Process. I request you to receive the report prepared by me on the basis of my findings. The internship program and writing this report has been a great pleasure and an extremely interesting and rewarding experience. It has enabled me to get an insight into the practical arena of Human Resource Department and more specifically into the area of Recruitment and Selection Process. I tried my level best to complete this report properly and to produce a meaningful report within all the constraints. I would be glad to furnish you with any clarifications, if required. I therefore, submit it, hoping that you would excuse the minor flaws. Thank You. Sincerely Abida Ferdous ID-10304070 Dept of BBS Acknowledgement I was given the opportunity to prepare a report for my internship program under the supervision of our honorable supervisor of Internship.
  • 2020 Korea Innovative PHAR

    2020 Korea Innovative PHAR

    2020 This brochure illustrates a project promoted by Korean pharmaceutical companies and with support from the Korean government, to enter global markets. You’ll meet the Korean pharmaceutical industry as a reliable partner for global collaboration. Contents 02 Current Status of Korean Pharmaceutical Market 08 Introduction of Korean Innovative Pharmaceutical Company Certification System 10 Information of Korean Innovative Pharmaceutical Company 55 Supplement Current Status of Korean Pharmaceutical Market Current Status of (Market size) Korean pharmaceutical market passed the $21 billion mark in 2018. Its Korean Pharmaceutical Market growth has been driven by leading Korean companies, which have been releasing new global drugs and achieving technology exports. Pharmaceuticals exports have increased at a CAGR of 17.9% for the past five years (2014-2018), fueled especially by increases in Korean drugs entering into global markets. Current status of Korean pharmaceutical market (unit: million dollar, %) Year-on-year CAGR Category 2014 2015 2016 2017 2018 growth rate (’14~’18) Market size 18,396 16,963 18,712 19,508 21,004 7.70% 3.40% Production 15,593 14,991 16,198 18,000 19,176 6.50% 5.30% Exports 2,416 2,946 3,119 4,069 4,673 14.80% 17.90% Imports 5,219 4,918 5,633 5,577 6,501 16.60% 5.60% Trade balance △2,803 △1,972 △2,514 △1,508 △1,828 △21.2% △10.1% * Source: Press release by the Ministry of Food and Drug Safety (July 29 2019) • ‌The 2018 sales revenue of the listed drug companies (125) is $18,172 million in total (7.5% up from the previous year), with Top 10’s revenue at $7,814 million (8.6%↑).
  • Employment of Veterinarians

    Employment of Veterinarians

    CONTENTS TOPIC PAGE Foreword 1 Summary of Project Since 1965 5 Veterinary Medicine in Kenya The Livestock Industry 8 Employment of Veterinarians 11 Livestock Diseases 14 Zoonoses 16 Research, Extension and Continuing Education 17 Operational Plan, Contract AID/afr-790 21 Scope of Work 22 Contract Staff 22 History of the Faculty of Veterinary Medicine 24 Beginning of Colorado State University Program of Technical Assistance 27 Faculty of Veterinary Medicine Structure 29 Undergraduate Program of Study 29 Structure of Curriculum 30 Courses of Study 30 Examination Sche2me 31 Outlines of Courses 33 Postgraduate Programs of Study 39 Faculty of Veterinary Medicine, Departmental Structure Clinical Studies 41 Pathology and Microbiology 43 Anatomy and Histology 45 Animal Physiology 46 Public Health, Pharmacology and Toxicology 47 Kenyanization of the Faculty 48 Government of Kenya Contribution to the Project 49 Professional Staff Supplied by C.S.U. Field Staff in Nairobi 54 Campus Coordinators 60 Administrative Staff 60 Recruitment of Field Staff 62 Publications by C.S.U. Field Staff 64 Publications by Counterparts 66 Unpublished Research 68 Post Graduate Courses 69 Graduate Student Supervision 70 International Meetings 72 External Examiners from C.S.U. 73 Participant and Counterpart Training Summary 74 Distribution of Participants in U.S. Universities 74 Selection of Participants 75 Support of Participants Upon Return-to Kenya 77 Participants 78 Counterpart Training 85 Final Reports of Field Staff Parasitology, Dr. A. E. Sollod 87 Clinical Studies,
  • WHO Monographs on Selected Medicinal Plants. Volume 3

    WHO Monographs on Selected Medicinal Plants. Volume 3

    WHO monographs on WHO monographs WHO monographs on WHO published Volume 1 of the WHO monographs on selected medicinal plants, containing 28 monographs, in 1999, and Volume 2 including 30 monographs in 2002. This third volume contains selected an additional collection of 32 monographs describing the quality control and use of selected medicinal plants. medicinal Each monograph contains two parts, the first of which provides plants selected medicinal plants pharmacopoeial summaries for quality assurance purposes, including botanical features, identity tests, purity requirements, Volume 3 chemical assays and major chemical constituents. The second part, drawing on an extensive review of scientific research, describes the clinical applications of the plant material, with detailed pharmacological information and sections on contraindications, warnings, precautions, adverse reactions and dosage. Also included are two cumulative indexes to the three volumes. The WHO monographs on selected medicinal plants aim to provide scientific information on the safety, efficacy, and quality control of widely used medicinal plants; provide models to assist Member States in developing their own monographs or formularies for these and other herbal medicines; and facilitate information exchange among Member States. WHO monographs, however, are Volume 3 Volume not pharmacopoeial monographs, rather they are comprehensive scientific references for drug regulatory authorities, physicians, traditional health practitioners, pharmacists, manufacturers, research scientists
  • Annual Report 2019-2020

    Annual Report 2019-2020

    Annual Report 2019-2020 SQUARE PHARMASince 1958 Square Pharmaceuticals Ltd About Us SQUARE Pharma, the largest pharmaceu�cals company in the Country, is a trusted name in the pharmaceu�cals sector of Bangladesh. Like most indigenous concern it made its debut in a humble way in 1958 as a Partnership Firm under the leadership of Late Samson H Chowdhury. The following year, 12 working people, occupied floor space of 3,000 sq. �., first produc�on EASTON’S syrup and made a turnover of Tk. 55,000. In 1964, Partnership Firm converted into a Private Limited Company, then in 1991, converted into a Public Limited Company and become Publicly Listed Company in 1995. SQUARE today symbolizes a name - a state of mind. From the incep�on in 1958, it has today burgeon into one of the top line conglomerates in Bangladesh. SQUARE Pharma, the flagship company, is holding the strong leadership posi�on (#1) in the pharmaceu�cal industry of Bangladesh since 1985. It has extended its range of services towards the highway of Market Leader global market. It pioneered exports of medicines from Since 1985 Bangladesh in 1987 and has been expor�ng an�bio�cs and other pharmaceu�cal products. This extension in business and services has manifested the credibility of SQUARE Pharma. SQUARE Pharma is to emphasize on the quality of product, process and services leading to grow of the company imbibed with good governance prac�ces. Square Pharmaceu�cals Ltd. Square Pharmaceu�cals www.squarepharma.com.bd Since 1958 Since Performance Key Highlights SQUARE PHARMA Standalone 18.68
  • Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea

    Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea

    2018 Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea Aging populations and growing interest in health and welfare continue to drive up the demand for innovative drugs across the world. Globally, R&D spending in the pharmaceutical industry was higher than any other industry (pharmaceutical and bio ranked No. 1 with 150 billion dollars(2015)), indicating that the future industrial structure is shifting from IT to pharmaceutical business. Pharmaceutical Industry in Korea In Korean, the value of drugs manufactured in Korea was KRW 18.8 trillion in 2016. The annual average growth rate for the past five years was 4.6 percent. In addition, the size of the pharmaceutical market was KRW 21.7 trillion in 2016. Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion) Category Production Export Import Balance Market size 2012 157,140 23,409 58,535 △35,126 192,266 2013 163,761 23,306 52,789 △29,483 193,244 2014 164,194 25,442 54,952 △29,510 193,704 2015 169,696 33,348 56,016 △22,668 192,364 2016 188,061 36,209 65,404 △29,195 217,256 YOY 10.8% 8.6% 16.8% - 12.9% CAGR(’12~’16) 4.6% 11.5% 2.8% - 3.1% Note: 1) Pharmaceutical products include finished products, narcotic drugs, ultra narcotic, psychotropic substance and drug substance 2) Numbers in export and import categories are calculated in Korean won and converted US dollar by using annual average exchange rate at Bank of Korea 3) Market Size= Production-Export+Import Source: Pharmaceutical Industry Statistics, Korea Pharmaceutical and Bio-Pharma Manufacturers Association Facts & Survey Report, Korea Pharmaceutical Traders Association, Korea Health Industry Statistics System Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical trials and drug manufacturing.
  • Socio-Economic Responsibility of Pharmaceutical Companies: Bangladesh Case

    Socio-Economic Responsibility of Pharmaceutical Companies: Bangladesh Case

    Research Article, ISSN 2304-2613 (Print); ISSN 2305-8730 (Online) Socio-Economic Responsibility of Pharmaceutical Companies: Bangladesh Case Nahid Akter Lecturer, School of Business, Asian University of Bangladesh, Dhaka, BANGLADESH *E-mail for correspondence: [email protected] https://doi.org/10.18034/abr.v8i3.165 ABSTRACT Bangladesh is a rustic of rising economy. The causes of its rising is high rate of industrialization and investment in different sectors. The pharmaceutical sector that is the second largest export earning source of the country after Ready Made Garments contributes almost 1% of the GDP and is currently the third largest tax paying sector in the country. Square Pharmaceutical Limited (SPL) the biggest name in the pharmaceutical sector of Bangladesh has a market share of 19.3% and the total exporting amount become BDT 1,137.99 millions in FY 2016-2017 that is 34.46% more than the previous year. This paper is almost done using the secondary data though a slight primary data is used where customer’s choice is examined where the highest 38% of the customer like the brand name square. This study assessed and examined the role of pharmaceutical company to the economy of Bangladesh from the perspective of square pharmaceutical limited as the sample company. The researcher also investigates the corporate social responsibility activities played by the respective company. This paper will be useful to the pharmaceutical companies, concerned authorities, policy makers and the government to know the role of pharmaceutical sector and required initiatives to eliminate all the hindrances and resolve all the problems to make out pharmaceutical sector as a crucial actor in both domestic and international market.
  • MINUTES of 229Th MEETING of CENTRAL LICENSING BOARD

    MINUTES of 229Th MEETING of CENTRAL LICENSING BOARD

    MINUTES OF 257th MEETING OF CENTRAL LICENSING BOARD HELD ON JANUARY 24-25, 2018 *=*=*=*=* 257th meeting of the Central Licensing Board (CLB) was held on January 24-25, 2018 in the Committee Room, Drug Regulatory Authority of Pakistan, 4th Floor, T.F. Complex, G-9/4, Islamabad under the Chairmanship of Mr. Ghulam Rasool Dutani, Director Drug Licensing, Drug Regulatory Authority of Pakistan, Islamabad. Following members attended the meeting: - S. No. Name & Designation Status 1. Dr. Sheikh Akhter Hussain. Member Director (QA/LT), DRAP, Islamabad Mr. Munawar Hayat, Member 2. Chief Drug Controller, Primary and Secondary Health Care Department, Govt. of Punjab, Lahore Syed Welayat Shah, Member 3. Chief Drug Inspector, Department of Health, Govt. of Khyber Pakhtunkhwa, Peshawar Syed Saleem Shah, Member 4. Chief Drug Inspector, Department of Health, Govt. of Balochistan, Quetta 5. Syed Muied Ahmed, Expert in manufacturing of drugs. Member 6. Dr.Ikram-ul-Haque , Expert inQC/QA of drugs. Member 7. Prof. Dr. Abdullah Dayo, Dean, Faculty of Pharmacy, University of Member Sindh, Jamshoro 8. Prof. Dr. Mohammad Usman, Expert in manufacturing of drugs Member 9. Prof Dr. Jamshaid Ali Khan, Department of Pharmacy, University of Member Peshawar, Peshawar Mr. KhurramShahzad Mughal, Member 10. Consultant M/o Law, Justice and Human Rights, as representative of M/o Law and Justice, Islamabad. 11. Mr. Manzoor Ali Bozdar, Additional Director (Lic.), DRAP, Secretary/Member Islamabad. 12. Mr Sabooor Ahmed Sheikh and Mr. Arshad Mehmood as Observer Representatives of PPMA 13. Mr. Nadeem Alamgir, Representative of Pharma Bureau. Observer 14. Mr. Kamran Anwar, Representative of PCDA. Observer The meeting started with the recitation of verses from the Holy Qura’an.